Top

Journal of Neurology

Published in:

01-03-2019 | Letter to the Editors

Charles Bonnet syndrome in Leber’s hereditary optic neuropathy

Authors: Hana Kolarova, Claudia B. Catarino, Claudia Priglinger, Thomas Klopstock

Published in: Journal of Neurology | Issue 3/2019

Excerpt

Dear Sirs, …

Pang L (2016) Hallucinations experienced by visually impaired: Charles Bonnet syndrome. Optom Vis Sci 93:1466–1478CrossRefPubMedCentralPubMed

Hedges TR (2007) Charles Bonnet, his life, and his syndrome. Surv Ophthalmol 52:111–114CrossRefPubMed

Santos-Bueso E, Saenz-Frances F, Porta-Etessam J, Garcia-Sanchez J (2014) Charles Bonnet syndrome triggered by brimonidine in a patient with Leber’s hereditary optic neuropathy. Rev Psiquiatr Salud Ment 7:152–153CrossRefPubMed

Santhouse AM, Howard RJ, ffytche DH (2000) Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 123:2055–2064CrossRefPubMed

Sacai PY, Salomao SR, Carelli V et al (2010) Visual evoked potentials findings in non-affected subjects from a large Brazilian pedigree of 11778 Leber’s hereditary optic neuropathy. Doc Ophthalmol 121:147–154CrossRefPubMed

Menon GJ, Rahman I, Menon SJ, Dutton GN (2003) Complex visual hallucinations in the visually impaired: the Charles Bonnet syndrome. Surv Ophthalmol 48:58–72CrossRefPubMed

Title: Charles Bonnet syndrome in Leber’s hereditary optic neuropathy
Authors: Hana Kolarova
Claudia B. Catarino
Claudia Priglinger
Thomas Klopstock
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 3/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09205-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Charles Bonnet syndrome in Leber’s hereditary optic neuropathy

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Moyamoya angiopathy: long-term follow-up study in a Finnish population

A case of anaphylaxis to alemtuzumab

Patient MW: transient visual hemi-agnosia

Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson’s disease: a first experience

Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe

Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review